CISH

ONK Therapeutics and NAYA Biosciences Announce Research Partnership to Advance Combination Therapy of Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies and FLEX-NK™ Bispecific Antibodies

Retrieved on: 
Wednesday, December 6, 2023
KO, AACR, Partnership, Survival, Tumor microenvironment, Antigen, Immunotherapy, Research, Kis, Natural killer T cell, Regenerative medicine, SAN, NCR1, Therapy, Fertility, Cancer, HCC, Society, CISH, Patient, GPC3, NK, FLEX, SITC

Specifically, the partnership will explore the combination of ONK’s ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy with NAYA’s GPC3-targeted NY-303 FLEX-NK™ bispecific antibody.

Key Points: 
  • Specifically, the partnership will explore the combination of ONK’s ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy with NAYA’s GPC3-targeted NY-303 FLEX-NK™ bispecific antibody.
  • The companies’ R&D teams will collaboratively evaluate ONK’s optimally gene-edited NK cell therapy, ONKT105, with NAYA’s NY-303 bispecific antibody before selecting the best candidates for potential clinical development.
  • ONK has exclusive, worldwide rights to KO of CISH in NK cells, regardless of the source of the NK cells.
  • They redirect and trigger the killing activity of Natural Killer (NK) cells towards their tumor targets using NKp46 activating receptors.

NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

Retrieved on: 
Wednesday, December 6, 2023
KO, Research, Fertility, SAN, Hepatocellular carcinoma, Therapy, Natural killer T cell, Kis, Patient, NCR1, Tumor microenvironment, Regenerative medicine, GPC3, CISH, NK, Immunotherapy, Cancer, Survival, SITC, Partnership, HCC, Daily Naya Diganta, Neoplasm, FLEX, Society, Cell, AACR, Pharmaceutical industry, Vaccine

Specifically, the partnership will explore the combination of NAYA's GPC3-targeted NY-303 FLEX-NK™ bispecific antibody with ONK's ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy.

Key Points: 
  • Specifically, the partnership will explore the combination of NAYA's GPC3-targeted NY-303 FLEX-NK™ bispecific antibody with ONK's ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy.
  • NAYA and ONK plan to assess several combination therapies in preclinical cancer models in 2024 prior to subsequently exploring initiating clinical trials.
  • NAYA's FLEX-NK™ bispecific antibodies are built on a proprietary tetravalent, multifunctional format with flexible linker, facilitating simultaneous binding to different antigens on one or multiple cells.
  • ONK has exclusive, worldwide rights to KO of CISH in NK cells, regardless of the source of the NK cells.

European Patent Office Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies

Retrieved on: 
Tuesday, June 27, 2023
CISH, Medicine, European Patent Office, NK, Research, IP, Commercialization, EPO, KO, Cell, WEHI, Patent, Patient, SAN, European Patent Convention, Drug discovery, Therapy, Natural killer T cell, Pharmaceutical industry, Biotechnology

ONK licensed the patent family relating to the KO of CISH in NK cells in an exclusive global patent license agreement from WEHI in 2021.

Key Points: 
  • ONK licensed the patent family relating to the KO of CISH in NK cells in an exclusive global patent license agreement from WEHI in 2021.
  • CISH KO has been shown to improve the persistence, metabolic profile, and cytotoxicity of NK cells.
  • The patent granted by EPO specifically covers CISH KO NK cells per se, and cancer therapies that utilize NK cells with CISH KO as well as NK cells engineered with the foundational CISH KO in combination with IL-15 (soluble or engineered), TGFβR2 KO, or TGFβR2 KO and IL-15 (soluble or engineered).
  • We believe this is the foundational CISH KO patent, based on the earliest scientific discoveries and covers CISH KO NK cells from any source.

Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting

Retrieved on: 
Monday, April 17, 2023
Rituximab, CRISPR, AACR, CD16, ADCC, CISH, Bacterial conjugation, Cancer, Head, NK, HL60, Doctor of Philosophy, Cetuximab, CAR, Immunoglobulin G, EGFR, CD62L, ADAM17, Vaccine

SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of two preclinical data abstracts focused on its natural killer cell pipeline and proprietary manufacturing technology at the 2023 American Association of Cancer Research (AACR) Annual Meeting.

Key Points: 
  • ADAM17 KO NK cells maintain dramatically higher surface expression of CD16a and CD62L than control NK cells.
  • ADAM17 KO CD19 CAR NK cells demonstrate higher cytotoxicity compared to control NK cells against Raji tumor cells in the presence of rituximab (anti-CD20).
  • Furthermore, ADAM17/CISH/CBLB triple KO CD70 CAR NK cells have improved antitumor efficacy in vivo in an HL60 AML xenograft model.
  • These data support the further exploration of ADAM17 KO CAR NK cells for clinical application and to improve the efficacy of therapeutic antibodies in combination with the adoptive transfer of engineered NK cells.

HR Positive/ Her2 Negative Breast Cancer - Pipeline Insight, 2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 22, 2023
Health, Oncology, CISH, Sequela, Triple-negative breast cancer, FISH, Therapy, Cleavage, HER2, CDK, Bone metastasis, Survival, Clinical trial, Route of administration, Quality of life, Lead, Woman, ERBB2, AstraZeneca, Rated R, IHC, II, Sapporo Medical University, Combination therapy, Route, Daiichi Sankyo, Administration, US, Discovery, ET, Patient, Breast cancer, Risk, DXD, Immunoglobulin G, HR, In situ hybridization, Immunohistochemistry, ADC, Growth, Mortality, Spacecraft, Lymph node, Recurrence, News, III, SERD, DFS, Birth control, Medical imaging, Pharmaceutical industry, Dietary supplement, Fine chemical

This "HR Positive/ HER2 Negative Breast Cancer - Pipeline Insight, 2023" report provides comprehensive insights about 50+ companies and 53+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape.

Key Points: 
  • This "HR Positive/ HER2 Negative Breast Cancer - Pipeline Insight, 2023" report provides comprehensive insights about 50+ companies and 53+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape.
  • Depending on the levels of HER2 or ERBB2 in the laboratory test breast cancer is classified as HER2 or ERBB2 positive or HER2 negative breast cancer.
  • A detailed picture of the HR Positive/ HER2 Negative Breast Cancer pipeline landscape is provided which includes the disease overview and HR Positive/ HER2 Negative Breast Cancer treatment guidelines.
  • HR Positive/ HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

In Situ Hybridization Global Market Report 2022: Technological Advancements in the Field of In Vitro Diagnostics Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 8, 2023
Medical Devices, Health, Interview, Ageing, Diagnosis, Medicare, Dicarboxylic acid, Insurance, Incidence, Application, Research, Immunohistochemistry, USD, Autopsy, Chromosome, DNA, DSM-IV codes, Bracewell probe, Patient, Cancer, Discovery Green, Drug development, Elsevier, ISH, Maintenance, COVID-19, RNA, Placenta, Pharmaceutical industry, Vaccine, CISH, FISH

The global in situ hybridization market size is expected to reach USD 2.42 billion by 2030 and is set to expand at 6.9% CAGR from 2023 - 2030.

Key Points: 
  • The global in situ hybridization market size is expected to reach USD 2.42 billion by 2030 and is set to expand at 6.9% CAGR from 2023 - 2030.
  • Situ Hybridization (ISH) is extensively utilized for research and clinical applications of diagnostics.
  • The increasing awareness about ISH techniques and their usage encourages researchers to employ the techniques for various applications.
  • Increasing outsourcing to ensure high adherence to quality standards and improve operational functionalities contributes to the lucrative growth
    4.1 In Situ Hybridization Market: Technology Movement Analysis
    5.1 In Situ Hybridization Market: Probe Movement Analysis
    6.1 In Situ Hybridization Market: Product Movement Analysis

ONK Therapeutics Boosts Drug Development Experience and Expands US Presence with the Appointment of Bruce McCreedy Ph.D. as Chief Scientific Officer

Retrieved on: 
Tuesday, December 6, 2022
Virology, CD96, DR4, GMP, NK, McCreedy, DR5, Tumor microenvironment, Research, Lymphatic system, SAN, LNP, School, Medicine, Cancer, TNF, Microbiology, CD38, Hope, Doctor of Philosophy, CISH, Drug development, WEHI, Intellia Therapeutics, Patient, JLab Audio, CSO, IND, CRISPR, Gilead Sciences, Therapy, University, Management, Pharmaceutical industry, Organon, Hematology

He has been responsible for leading research organizations through the design and execution of highly successful drug development programs including currently marketed products.

Key Points: 
  • He has been responsible for leading research organizations through the design and execution of highly successful drug development programs including currently marketed products.
  • He joins ONK Therapeutics from Myeloid Therapeutics, Inc., where as CSO his responsibilities included all IND-enabling pre-clinical studies.
  • Bruce McCreedy Ph.D., CSO of ONK Therapeutics said, “I am excited to be joining ONK Therapeutics at a pivotal time in its development as it navigates its path towards clinical trials.
  • ONK Therapeutics is headquartered in the med-tech hub of Galway, Ireland, with a wholly-owned USA subsidiary, ONK Therapeutics, Inc. based at JLabs @ San Diego.

In Situ Hybridization Global Market Report 2022: Rising Incidence of Genetic Disorders and Cancer Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 30, 2022
Other Science, Science, Growth, Hospital, Diagnosis, Antibody, Cros, Prevalence, RNA, DNA, Conditional sentence, PNA, Patient, USD, Biomarker, Row, Consumables, Medicare, Gene amplification, ISH, Medical device, Pharma, Neuroscience, Software, Cancer, Biotechnology, CISH, Immunology

The global in situ hybridization market is projected to reach USD 2.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 12.6% during the forecast period.

Key Points: 
  • The global in situ hybridization market is projected to reach USD 2.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 12.6% during the forecast period.
  • FISH-based biomarkers play a substantial role in developing companion diagnostics because of their ability to evaluate morphology and gene amplification simultaneously.
  • Based on the end users the global in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies.
  • The in situ hybridization market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period.

ONK Therapeutics Presents Promising In-Vivo Data of its Optimized Affinity CD38 CAR-NK Candidate, Being Developed for the Treatment of Multiple Myeloma

Retrieved on: 
Monday, August 29, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, DR5, Cancer, CD96, NOD, NK, Tumor microenvironment, Survival, SCID, CAR, Therapy, Biotechnic & Histochemistry, Multiple myeloma, Mouse, Poster, CD38, CISH, NSG, CSO, TNF, Lymphatic system, JLab Audio, Cas9, CRISPR, DR4, Metabolism, Patient, Pharmaceutical industry, Medical imaging, Vaccine

ONKT102 is the companys most advanced program, and is being advanced towards clinical development as a potential treatment for patients with relapsed or refractory multiple myeloma (MM).

Key Points: 
  • ONKT102 is the companys most advanced program, and is being advanced towards clinical development as a potential treatment for patients with relapsed or refractory multiple myeloma (MM).
  • The anti-tumor efficacy of the optimized CD38 CAR-NK cells was then evaluated in NOD scid gamma (NSG) mice inoculated with MM.1S-LUC cells.
  • Prof. Michael ODwyer, founder and CSO at ONK Therapeutics said, These results suggest that non-virally engineered, optimized affinity CD38 CAR-NK CD38 KO cells have potent anti-tumor activity in-vitro and in-vivo in a CD38 positive tumor model.
  • ONK Therapeutics is headquartered in the med-tech hub of Galway, Ireland, with a wholly-owned US subsidiary, ONK Therapeutics, Inc. based at JLabs @ San Diego.

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022

Retrieved on: 
Thursday, May 5, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Other Health, COVID-19, Cancer, U.S. Securities and Exchange Commission, CD38, Private Securities Litigation Reform Act, Tumor necrosis factor, Hematological Cancer Research Investment and Education Act, Multiple myeloma, B cell, Instagram, Twitter, Immortalised cell line, Chronic myelogenous leukemia, Cell, RPMI, Safety, CA, Poster, Phenotype, Patient, Immunotherapy, PST, Security (finance), ISCT, FDA, LAMP1, Risk, K562, Therapy, Facebook, Lymphatic system, LinkedIn, MM, SEC, Hematology, Technology, International Society, NAM, CISH, NK, Vaccine, Communications satellite, Pharmaceutical industry

GDA-301 is an investigational genetically modified NAM-NK cell therapy candidate aimed at targeting hematologic malignancies and solid tumors.

Key Points: 
  • GDA-301 is an investigational genetically modified NAM-NK cell therapy candidate aimed at targeting hematologic malignancies and solid tumors.
  • The potency and cytotoxicity data suggest that GDA-301 represents a novel potential immunotherapeutic targeting hematologic malignancies as well as solid tumors.
  • GDA-601 is an investigational genetically engineered NAM-NK cell therapy candidate designed to target multiple myeloma (MM) cells.
  • Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapies for patients with solid tumor and blood cancers and other serious blood diseases.